進階搜尋


下載電子全文  
系統識別號 U0026-0611201714081500
論文名稱(中文) 探討三磷酸腺苷敏感型鉀離子通道的運輸對於脂肪酸誘導胰島貝他細胞凋亡中之角色
論文名稱(英文) Study on ATP sensitive potassium (KATP) channel trafficking in free fatty acid induced apoptosis of pancreatic β; -cells in vivo and in vitro
校院名稱 成功大學
系所名稱(中) 生理學研究所
系所名稱(英) Department of Physiology
學年度 106
學期 1
出版年 106
研究生(中文) 阮瀞萱
研究生(英文) Jing-Syuan Ruan
電子信箱 dory81423@hotmail.com.tw
學號 S36034091
學位類別 碩士
語文別 英文
論文頁數 40頁
口試委員 指導教授-陳珮君
召集委員-郭余民
口試委員-陳韻雯
中文關鍵字 三磷酸線苷敏感型鉀離子通道  脂毒性 
英文關鍵字 KATP channel  lipotoxicity 
學科別分類
中文摘要 代謝性症候群中以第二型糖尿病為最普遍,當過多脂肪酸累積在胰臟的
貝他細胞中會造成脂毒性的產生,譬如,促使貝他細胞進行自我凋亡導致功能逐漸喪失,因而引起胰島素釋放失去調控‧貝他細胞中胰島素的分泌主要與細胞膜上的三磷酸線苷敏感型鉀離子通道有關,此通道由四個Kir6.2 次單元SUR1 次單元所組成‧通道的開關主要受細胞內核苷酸的濃度的影響,故可以因應內分泌訊號及細胞代謝的狀況來分泌胰島素‧此研究主要目的為,探討過多的脂肪酸對於三磷酸線苷敏感型鉀離子通道運輸至膜上的影響‧棕梠酸是最廣泛存在於飲食及血液中的飽和脂肪酸‧我們發現長期由皮下給予棕梠酸的老鼠有著第二型糖尿病的疾病表徵‧從其胰臟切片可看到細胞內的胰島素及SUR1次單位的表現量上升,接下來我們利用INS-1 細胞株,給予不同濃度的棕梠酸並維持在不同的時間點來找尋適合的藥物劑量及給予時間‧由結果可以看到,在0.4 毫莫爾濃度進行72 小時刺激之下,增加的了細胞自我凋亡,但仍有百分之二十五的細胞仍然存活‧我們也發現到細胞表面上的SUR1 次單位表現量明顯下降‧過去研究指出利用藥理學的方法,給予其抑制劑glibenclamide 可以校正三磷酸線苷敏感型鉀離子通道運輸至膜上的的缺失‧而在我們的結果當中,glibenclamide 確實增加了細胞表面SUR1 次單位的表現量上升且下降貝他細胞的死亡‧而除了glibenclamide,當同時給予其活化劑diazoxide,發現可以抑制胰島素分泌來改善胰島素過多的情形‧而同時給予兩個藥物可以看到最顯著病徵改善,包括內質網壓力的減緩及粒線體膜電位的回覆‧更重要的是glibenclamide 改善了老鼠的葡萄糖耐受性,胰島素分泌及下降三酸甘油酯的濃度‧總結以上,三磷酸線苷敏感型鉀離子通道運輸至膜上的的缺失不只影響了胰島素的分泌更影響了貝他細胞的存活‧而透過給予glibenclamide 來校正此運輸的缺失後,進而使內質網壓力下降來增加細胞的存活率及改善葡萄糖平衡‧
英文摘要 Type 2 diabetes is the most prevalent metabolic syndrome worldwide and elevated systemic levels of fatty acids are now considered significant contributors towards the progression of this syndrome. Lipotoxicity is associated with the high level of fatty acid accumulation observed in the pancreatic β-cells. The overload of free fatty acid contributes to pancreatic β-cells apoptosis and
dysfunction. Insulin secretion is controlled by KATP channel which is an octameric complex of four pore-forming inwardly rectifying potassium channel Kir6.2 subunits and four sulfonylurea receptor 1 (SUR1) regulatory subunits. In addition to gating regulation by intraceullar nucleotides, KATP conductance is also determined by channel abundance in the plasma membrane. This study was aimed to investigate effects of lipotoxicity on trafficking of KATP channel in pancreatic β cell using chronic palmitic acid mice and cell models. Palmitic acid (Palm) is the most abundant free fatty acids (FFA) present in the diet and in serum. Chronic Palm-injected mice displayed type II diabetic characteristics. The pancreatic sections of these mice showed upregulated intracellular insulin granules
and protein expression of SUR1. Then, we tested time and dose effects of palmitic acid on the cell viability using rat insulinoma (INS-1) cells. Our results indicated that 25 % of cells after 72 hours of 0.4 mM palmitic acid stayed viable. We also found a significant decrease in the surface expression of SUR1. In addition, this treatment induced pancreatic β cells apoptosis by increasing cleaved caspase 3 proteins. Researches have shown that the pharmacological chaperone, glibenclamide, corrects trafficking defect of KATP channels. Our results showed glibenclamide increased surface SUR1 expression and decreased pancreatic β cell death. Upon increasing surface KATP channels in the plasma membrane, diazoxide, the KATP channel opener, can reduce insulin secretion.
Co-treatment with glibenclamide and diazoxide in Palm-treated cells showed the most promising rescued effect, the lowest ER stress and better mitochondrial membrane potential. Importantly,glibenclamide also improved glucose tolerance, triglyceride concentration and increased insulin release in Palm-injected mice. In conclusion, impaired trafficking of KATP channels not only affects insulin secretion but also pancreatic β cell death. The underlying mechanisms in which chronic palmitic acid-impaired KATP channel trafficking is associated ER stress, hence,glibenclamide as the pharmacological chaperone can rescue cells and improve glucose homeostasis.
論文目次 口試合格證明------------------- I
Abstract --------------------- II
中文摘要 ---------------------- III
誌謝--------------------------- IV
Contents ---------------------- VI
Figure Contents --------------- VII
Introduction ------------------- 1
Roles of free fatty acids (FFAs) in glucose homeostasis-1
Regulation of ATP sensitive potassium channel (KATP) --4
KATP channel and cell survival ---------------------- 7
Research rationales and hypothesis ----------------- 9
Specific aims -------------------------------------- 9
Materials and methods ------------------------------ 10
Preparation of Palm-BSA complex Solution ----------- 10
Animals and experimental Protocol ------------------ 11
Tissue samples harvesting -------------------------- 11
Cell culture and palmitic acid treatment ----------- 11
Oil red O staining --------------------------------- 12
Cell viability assay ------------------------------- 12
Detection of mitochondrial depolarization ---------- 12
Immunocytochemistry Examination -------------------- 13
Glucose tolerance test (GTT) ----------------------- 13
Immunohistochemical (IHC) Examination -------------- 13
Glucose stimulated insulin secretion assay --------- 14
Western blot --------------------------------------- 14
Surface biotinylation ------------------------------ 15
Microscope examination ----------------------------- 15
Image analysis ------------------------------------- 15
Statistical analysis ------------------------------- 16
Results -------------------------------------------- 16
Discussion ----------------------------------------- 21
Conclusion ----------------------------------------- 24
Figures -------------------------------------------- 25
References ----------------------------------------- 35
參考文獻 References
1. Rustan, A.C., Fatty Acids: Structures and Properties. ENCYCLOPEDIA OF LIFE SCIENCES, 2005: p. 1-7.
2. Nolan, C.J., Fatty Acid Signaling in the beta Cell and Insulin Secretion. DIABETES, 2006. 55(Supplement 2): p. S16-S23.
3. Yang, H., The role of fatty acid metabolism and lipotoxicity in pancreatic β-cell injury: Identification of potential therapeutic targets. Acta Pharmaceutica Sinica B, 2012. 2(4): p. 396-402.
4. Mirmira, R.G., Saturated free fatty acids: islet beta cell "stressERs". Endocrine,2012. 42(1): p. 1-2.
5. Back, S.H., Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem, 2012. 81: p. 767-793.
6. Sharma, R.B., Lipotoxicity in the pancreatic beta cell: not just survival and function,but proliferation as well? Curr Diab Rep, 2014. 14(6): p. 492-510.
7. Misler, S., A metabolite regulated potassium channel in rat pancreatic beta cells.Physiological Sciences, 1986. 83: p. 7119-7123.
8. Clement, J.P., Association and Stoichiometry of KATP Channel Subunits. Neuron, 1997. 18: p. 827–838.
9. Zerangue, N., A New ER Trafficking Signal Regulates the Subunit Stoichiometry of Plasma Membrane KATP Channels. Neuron, 1999. 22: p. 537–548.
10. Ficker, E., Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res, 2003. 92(12): p. 1-20.
11. Conti, L.R., Transmembrane Topology of the Sulfonylurea Receptor SUR1. J Biol Chem, 2001. 276: p. 41270–41278.
12. Akrouh, A., Molecular biology of K(ATP) channels and implications for health and disease. IUBMB Life, 2009. 61(10): p. 971-978.
13. Marroqui, L., Role of leptin in the pancreatic beta-cell: effects and signaling pathways. J Mol Endocrinol, 2012. 49(1): p. R9-17.
14. AGUILAR-BRYAN, L., Toward Understanding the Assembly and Structure of KATP Channels. PHYSIOLOGICAL REVIEWS, 1998. 78: p. 227-245.
15. Lee, A., More than a pore: ion channel signaling complexes. J Neurosci, 2014.34(46): p. 15159-69.
16. Kline, C.F., Dual role of K ATP channel C-terminal motif in membrane targeting and metabolic regulation. Proc Natl Acad Sci U S A, 2009. 106(39): p. 16669-74.
17. Curran, J., Alternative paradigms for ion channelopathies: disorders of ion channel membrane trafficking and posttranslational modification. Annu Rev Physiol, 2015.77: p. 505-524.
18. Sloane, P.A., Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med, 2010. 16(6): p.591-597.
19. Ratjen, F.A., Cystic Fibrosis Pathogenesis and Future Treatment Strategies. Respir Care, 2009. 54: p. 595-602.
20. Imai, M., Novel KCNQ1 splicing mutation in patients with forme fruste LQT1 aggravated by hypokalemia. J Cardiol, 2014. 64(2): p. 121-6.
21. Yang, Y., Identification of a Kir3.4 Mutation in Congenital Long QT Syndrome. The American Journal of Human Genetics, 2010. 86(6): p. 872-880.
22. Zivony-Elboum, Y., A founder mutation in Vps37A causes autosomal recessive complex hereditary spastic paraparesis. J Med Genet, 2012. 49(7): p. 462-472.
23. Tan, B.-H., Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine. Am J
Physiol Heart Circ Physiol, 2006. 291: p. H1822–H1828.
24. Valdivia, C.R., A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovascular Research, 2002. 55: p. 279–289.36
25. Martin, G.M., Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels. Front Physiol, 2013. 4: p. 1-16.
26. Nathan, D.M., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009. 32(1): p. 193-203.
27. Kramer, W., The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels. Diabetes Research and Clinical Practice, 1995. 28: p. S67-S80.
28. Shorr, R.I., Individual Sulfonylureas and Serious Hypoglycemia in Older People.Clinical investigation, 1996. 44: p. 751-755.
29. Group, U.P.D.S.U., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33). The Lancet, 1998. 352(9131): p. 837-853.
30. Kahn, S.E., Glycemic Durability of Rosiglitazone Metformin or Glyburide Monotherapy. The new england journal o f medicine, 2006. 355: p. 2427-2443.
31. Efanova, I.B., Glucose and Tolbutamide Induce Apoptosis in Pancreatic β Cells.THE JOURNAL OF BIOLOGICAL CHEMISTRY, 1998. 273: p. 33501–33507.
32. Iwakura, T., Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun, 2000. 271(2): p. 422-
428.
33. Maedler, K., Sulfonylurea Induced β Cell Apoptosis in Cultured Human Islets. The Journal of Clinical Endocrinology & Metabolism, 2005. 90: p. 501-506.
34. Del Guerra, S., Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications, 2005. 19(1): p.60-64.
35. Takahashi, A., Sulfonylurea and glinide reduce insulin content functional expression of KATP channels, and accelerate apoptotic beta cell death in the chronic phase. Diabetes Research and Clinical Practice, 2007. 77: p. 343-350.
36. Qian, L., Endoplasmic reticulum stress in beta cells: Latent mechanism of secondary sulfonylurea failure in type 2 diabetes? Medical Hypotheses, 2008. 71:p. 889-891.
37. Kwon, M.J., Low glibenclamide concentrations affect endoplasmic reticulum stress in INS-1 cells under glucotoxic or glucolipotoxic conditions. Korean J Intern Med,2013. 28(3): p. 339-46.
38. Su, H., Autophagy induced by glibenclamide serves as a defense against apoptosis in INS-1 rat insulinoma cells. Journal of Diabetes Mellitus, 2013. 03(03):
p. 122-128.
39. GULDSTRAND, M., improved beta cell function after short term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab, 2002. 28: p.
448-456.
40. Brown, R.J., Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes, 2008. 9(3 Pt 2): p. 14-22.
41. Ritzel, R.A., Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab, 2004. 89(2): p. 795-805.
42. Song, S.H., Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology, 2003.
144(8): p. 3399-3405.
43. Cnop, M., et al., Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. DIABETES, 2001.50(8): p. 1771-7.37
44. Butler, A.E., et al., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. DIABETES, 2003. 52(1): p. 102-10.
45. Yu, Y., et al., Serum levels of polyunsaturated fatty acids are low in Chinese men with metabolic syndrome, whereas serum levels of saturated fatty acids, zinc, and
magnesium are high. Nutr Res, 2012. 32(2): p. 71-7.
46. Matthews, D.R., et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
Diabetologia, 1985. 28(7): p. 412-9.
47. Unger, R.H. and Y.T. Zhou, Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. DIABETES, 2001. 50 Suppl 1: p. S118-21.
48. Gookin, J.L., et al., NF-kappaB-mediated expression of iNOS promotes epithelial defense against infection by Cryptosporidium parvum in neonatal piglets. Am J Physiol Gastrointest Liver Physiol, 2006. 290(1): p. G164-74.
49. Ellgaard, L. and A. Helenius, Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol, 2003. 4(3): p. 181-91.
50. Hohmeier, H.E., et al., Isolation of INS-1-derived cell lines with robust ATPsensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. DIABETES, 2000. 49(3): p. 424-30.
51. Ammala, C., et al., Inositol trisphosphate-dependent periodic activation of a Ca(2+)-activated K+ conductance in glucose-stimulated pancreatic beta-cells. Nature, 1991. 353(6347): p. 849-52.
52. Perlmutter, D.H., Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res, 2002. 52(6): p. 832-6.
53. Powers, E.T., et al., Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem, 2009. 78: p. 959-91.
54. Zhang, X., et al., Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell, 2008. 135(1): p. 61-73.
55. Yang, L., et al., Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab, 2010. 11(6): p. 467-78.
56. Ozcan, U., et al., Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 2006. 313(5790): p.1137-40.
57. Gottlieb, E., et al., Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ, 2003.
10(6): p. 709-17.
58. Mancini, A., et al., Biological and Nutritional Properties of Palm Oil and Palmitic Acid: Effects on Health. Molecules, 2015. 20(9): p. 17339-61.
59. Yang, Z.H., H. Miyahara, and A. Hatanaka, Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis, 2011. 10: p. 120.
60. Kusminski, C.M., et al., Diabetes and apoptosis: lipotoxicity. Apoptosis, 2009.14(12): p. 1484-95.
61. Lee, Y., et al., Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships.Proc Natl Acad Sci U S A, 1994. 91(23): p. 10878-82.
62. Shimabukuro, M., et al., Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A, 1998. 95(5): p. 2498-502.
63. Unger, R.H., Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie, 2005. 87(1): p. 57-64.
64. Koshkin, V., et al., Mitochondrial functional state in clonal pancreatic beta-cells exposed to free fatty acids. J Biol Chem, 2003. 278(22): p. 19709-15.38
65. Carlsson, C., L.A. Borg, and N. Welsh, Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in
vitro. Endocrinology, 1999. 140(8): p. 3422-8.
66. Schonfeld, P. and L. Wojtczak, Fatty acids decrease mitochondrial generation of reactive oxygen species at the reverse electron transport but increase it at the
forward transport. Biochim Biophys Acta, 2007. 1767(8): p. 1032-40.
67. Gudz, T.I., K.Y. Tserng, and C.L. Hoppel, Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem, 1997. 272(39): p. 24154-8.
68. Cnop, M., et al., Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005. 54 Suppl 2: p. S97-
107.
69. Welch, W.J., Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol, 2004. 15(1): p. 31-8.
70. Maattanen, P., et al., Protein quality control in the ER: the recognition of misfolded proteins. Semin Cell Dev Biol, 2010. 21(5): p. 500-11.
71. Aridor, M. and L.A. Hannan, Traffic jam: a compendium of human diseases that affect intracellular transport processes. Traffic, 2000. 1(11): p. 836-51.
72. Aridor, M. and L.A. Hannan, Traffic jams II: an update of diseases of intracellular
transport. Traffic, 2002. 3(11): p. 781-90.
73. Chen, Y., et al., ER-associated protein degradation is a common mechanism underpinning numerous monogenic diseases including Robinow syndrome. Hum Mol Genet, 2005. 14(17): p. 2559-69.
74. Anderson, M.P. and M.J. Welsh, Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains [published erratum appears in Science 1992 Dec 11;258(5089):1719]. Science, 1992. 257(5077): p.1701-4.
75. Qu, B.H., E. Strickland, and P.J. Thomas, Cystic fibrosis: a disease of altered protein folding. J Bioenerg Biomembr, 1997. 29(5): p. 483-90.
76. Cheng, S.H., et al., Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell, 1990. 63(4): p. 827-34.
77. Carlile, G.W., et al., Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem, 2007. 8(9): p. 1012-20.
78. Robert, R., et al., Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol, 2010. 77(6): p. 922-30.
79. Robert, R., et al., Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol, 2008. 73(2): p. 478-89.
80. Sampson, H.M., et al., Identification of a NBD1-Binding Pharmacological Chaperone that Corrects the Trafficking Defect of F508del-CFTR. Chem Biol,2011. 18(2): p. 231-42.81. Verkman, A.S., G.L. Lukacs, and L.J. Galietta, CFTR chloride channel drug discovery-inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.Curr Pharm Des, 2006. 12(18): p. 2235-47.
82. Lukacs, G.L. and A.S. Verkman, CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med, 2012. 18(2): p. 81-91.
83. Molinski, S., et al., Functional Rescue of F508del-CFTR Using Small Molecule Correctors. Front Pharmacol, 2012. 3: p. 160.
84. Yan, F., et al., Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor. J Biol Chem, 2004.279(12): p. 11096-105.
85. Corkey, B.E., et al., A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic beta-cells. J Biol Chem, 1989. 264(36): p. 21608-12.39
86. Larsson, O., et al., Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic beta-cell glucose sensitivity. J Biol Chem,
1996. 271(18): p. 10623-6.
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2019-11-07起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2019-11-07起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw